Dashboard
Manage Tickers

AUTL Autolus Therapeutics plc

Nasdaq autolus.com


$ 1.56 $ 0.04 (2.65 %)    

Friday, 31-Oct-2025 15:59:51 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.66 $ 0.66 (0.14 %)
SPY $ 682.07 $ 2.23 (0.33 %)
TLT $ 90.35 $ -0.27 (-0.3 %)
GLD $ 368.10 $ -2.01 (-0.54 %)
$ 1.55
$ 1.52
$ 1.54 x 22
$ 1.65 x 16
$ 1.50 - $ 1.59
$ 1.11 - $ 4.12
1,494,307
na
401.87M
$ 1.51
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-17-2024 03-31-2024 10-Q
7 03-21-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

autolus-obe-cel-shows-83-remission-rate-in-early-lupus-study-fda-backed-phase-2-next
Autolus' Obe-cel Shows 83% Remission Rate ...
10/27/2025 11:10:24

Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and deliv...

autolus-therapeutics-doses-first-patient-in-phase-1-bobcat-trial-evaluating-obe-cel-for-progressive-multiple-sclerosis
Autolus Therapeutics Doses First Patient I...
10/20/2025 11:09:39

needham-reiterates-buy-on-autolus-therapeutics-maintains-10-price-target
Needham Reiterates Buy on Autolus Therapeu...
10/20/2025 09:41:48

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

autolus-to-present-early-data-from-carlysle-study-of-obe-cel-in-severe-lupus-at-acr-convergence-2025
Autolus To Present Early Data From CARLYSL...
09/16/2025 12:19:30

Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and deliv...

wells-fargo-maintains-overweight-on-autolus-therapeutics-lowers-price-target-to-5
Wells Fargo Maintains Overweight on Autolu...
08/13/2025 12:50:02

Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target fro...

autolus-therapeutics-q2-eps-018-beats-024-estimate-sales-20923m-beat-12905m-estimate
Autolus Therapeutics Q2 EPS $(0.18) Beats ...
08/12/2025 11:05:08

Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of ...

Core News & Articles
Earnings Scheduled For August 12, 2025
08/12/2025 08:32:28

needham-reiterates-buy-on-autolus-therapeutics-maintains-10-price-target
Needham Reiterates Buy on Autolus Therapeu...
07/21/2025 13:59:51

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

autolus-therapeutics-aucatzyl-granted-european-marketing-authorization-for-relapsed-for-refractory-b-cell-precursor-acute-lymphoblastic-leukemia-in-adult-patients
Autolus Therapeutics' AUCATZYL Granted Eur...
07/21/2025 11:03:38

fda-eases-access-to-life-saving-gene-therapies-for-blood-cancers
FDA Eases Access To Life-Saving Gene Thera...
06/30/2025 12:36:39

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and a...

what-4-analyst-ratings-have-to-say-about-autolus-therapeutics
What 4 Analyst Ratings Have To Say About A...
06/12/2025 19:01:36

needham-reiterates-buy-on-autolus-therapeutics-maintains-10-price-target
Needham Reiterates Buy on Autolus Therapeu...
06/12/2025 16:01:34

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

autolus-therapeutics-reports-426-month-median-response-from-felix-study-showing-obe-cels-potential-for-long-term-remission-in-rr-b-all
Autolus Therapeutics Reports 42.6-Month Me...
06/12/2025 07:33:35

Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow upMore than half of patients...

autolus-therapeutics-announces-positive-chmp-opinion-for-obecabtagene-autoleucel-for-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia
Autolus Therapeutics Announces Positive CH...
05/23/2025 12:33:10

Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demo...

autolus-therapeutics-presents-clinical-data-updates-at-2025-european-hematology-association-congress
Autolus Therapeutics Presents Clinical Dat...
05/14/2025 13:35:10

autolus-therapeutics-q1-eps-026-inline
Autolus Therapeutics Q1 EPS $(0.26), Inline
05/08/2025 11:06:18

Core News & Articles
Earnings Scheduled For May 8, 2025
05/08/2025 08:33:13

mhra-grants-conditional-marketing-authorisation-for-autolus-therapeutics-aucatzyl-for-treatment-of-adult-patients-with-relapsed-or-refractory-b-cell-precursor-acute-lymphoblastic-leukemia
MHRA Grants Conditional Marketing Authoris...
04/25/2025 16:10:01

UK Medicines and Healthcare products Regulatory Agency (MHRA) authorisation based on FELIX clinical trial of obecabtagene autol...

needham-reiterates-buy-on-autolus-therapeutics-maintains-10-price-target
Needham Reiterates Buy on Autolus Therapeu...
04/10/2025 11:18:17

Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $10 price target.

12-health-care-stocks-moving-in-wednesdays-after-market-session
12 Health Care Stocks Moving In Wednesday'...
04/09/2025 21:05:58

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION